PharmAust (ASX: PAA) executive chairman and CEO Dr Roger Aston joins Small Caps to discuss the company's latest news on monepantel which is set to commence a Phase 1 COVID-19 trial in humans in the near term. This comes after successfully repeating a second round of in-vitro anti-viral confirmatory testing, demonstrating anti-SARS-CoV-2 activity of both its monepantel and monepantel sulfone drug candidates. Dr Aston also discusses US veterinary pharmaceutical company Elanco US Inc decision not to proceed with exercising its option to develop monepantel as a cancer treatment for dogs and what this means for the company.See omnystudio.com/listener for privacy information.

Ver todos los episodios